ABSI vs. OABI, ORIC, MXCT, TSHA, OFIX, CMPS, SIGA, ALT, PLSE, and YMAB
Should you be buying Absci stock or one of its competitors? The main competitors of Absci include OmniAb (OABI), ORIC Pharmaceuticals (ORIC), MaxCyte (MXCT), Taysha Gene Therapies (TSHA), Orthofix Medical (OFIX), COMPASS Pathways (CMPS), SIGA Technologies (SIGA), Altimmune (ALT), Pulse Biosciences (PLSE), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "medical" sector.
OmniAb (NASDAQ:OABI) and Absci (NASDAQ:ABSI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, community ranking, analyst recommendations, profitability and valuation.
OmniAb presently has a consensus price target of $9.00, suggesting a potential upside of 109.30%. Absci has a consensus price target of $9.25, suggesting a potential upside of 109.75%. Given OmniAb's higher probable upside, analysts clearly believe Absci is more favorable than OmniAb.
OmniAb has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500.
In the previous week, Absci had 2 more articles in the media than OmniAb. MarketBeat recorded 4 mentions for Absci and 2 mentions for OmniAb. Absci's average media sentiment score of 1.88 beat OmniAb's score of 1.09 indicating that OmniAb is being referred to more favorably in the media.
OmniAb has higher revenue and earnings than Absci. OmniAb is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
OmniAb has a net margin of -301.62% compared to OmniAb's net margin of -2,042.01%. Absci's return on equity of -19.93% beat OmniAb's return on equity.
72.1% of OmniAb shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 8.6% of OmniAb shares are held by company insiders. Comparatively, 9.8% of Absci shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Absci received 4 more outperform votes than OmniAb when rated by MarketBeat users. However, 100.00% of users gave OmniAb an outperform vote while only 53.66% of users gave Absci an outperform vote.
Summary
OmniAb beats Absci on 9 of the 16 factors compared between the two stocks.
Get Absci News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
